Urinary excretion of advanced glycation endproducts in patients with type 2 diabetes and various stages of proteinuria

Diabetes and Metabolism

Volumn 30, Issue 2, 2004, Pages 187-192

  Turk, N ^a   Mornar, A ^b   Mrzljak, V ^a   Turk, Z ^a  

^a University of Zagreb   (Croatia)

^b UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Advanced glycation endproduct; Diabetic proteinuria; Renal function

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALBUMIN; ANTIDIABETIC AGENT; CELL PROTEIN; CREATININE; INSULIN;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; COMPETITIVE INHIBITION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION; FEMALE; HUMAN; IMMUNOREACTIVITY; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MULTIPLE REGRESSION; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION; PROTEIN URINE LEVEL; PROTEINURIA; STATISTICAL SIGNIFICANCE; URINARY EXCRETION;

EID: 2642541707     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1262-3636(07)70106-4     Document Type: Article

References (27)

1. Singh R, Barden A, Mori T, Belin L. Advanced glycation endproducts: a review. Diabetologia, 2002, 44, 129-46.
2. Frye EB, Degenhardt TP, Thorpe SR, Baynes JW. Role of the Maillard reaction in aging of tissue proteins. J Biol Chem, 1998, 273, 18714-9.
3. Thornalley PJ, Langborg A, Minhas HS. Formation of glyoxal, methylglyoxal and 3-DG in the glycation of proteins. Biochem J, 1999, 344, 109-16.
4. Wautier JL, Guillausseau PJ. Advanced glycation end products, their receptors and diabetic angiopathy. Diabete Metab, 2001, 27, 535-42.
5. Niwa T, Katsuzaki T, Miyazaki S, et al. Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients. J Clin Invest, 1997, 99, 1272-80.
6. Suzuki D, Miyata T, Saotome N, et al. Immunohistochemical evidence for an increased oxidative stress and carbonyl modification of proteins in diabetic glomerular lesions. J Am Soc Nephrol, 1999, 10, 822-32.
7. Uchida K, Khor OT, Oya T, Osawa T, Yasuda Y, Miyata T. Protein modification by Maillard reaction intermediate methylglyoxal-immunochemical detection of fluorescent 5-methylimidazolone derivatives in vivo. FEBS Lett, 1997, 410, 313-8.
8. Berg TJ, Bangstad HJ, Torjesen PA, Osterby R, Bucala R, Hanssen KF. Advanced glycation end products in serum predict changes in the kidney morphology of patients with insulin-dependent diabetes mellitus. Metabolism, 1997, 46, 661-5.
9. Morcos M, Sayed AAR, Bierhaus A, et al. Activation of tubular epithelial cells in diabetic nephropathy. Diabetes, 2002, 51, 3532-44.
10. Nakamura S, Tachikawa T, Tobita K, et al. An inhibitor of advanced glycation end product formation reduces N-epsilon-(carboxymethyl) lysine accumulation in glomeruli of diabetic rats. Am J Kidney Dis, 2003, 41, S68-S71.
11. Vlassara H. The AGE-receptor in the pathogenesis of diabetic complications. Diabetes Metab Res Rev, 2001, 17, 436-43.
12. Yanagisawa K, Makita Z, Shiroshita K, et al. Specific fluorescence assay for advanced glycation end products in blood and urine of diabetic patients. Metabolism, 1998, 47, 1348-53.
13. Shimoike T, Inoguchi T, Umeda F, Nawata H, Kawano K, Ochi H. The meaning of serum levels of advanced glycosylation end products in diabetic nephropathy. Metabolism, 2000, 49, 1030-5.
14. ε -(carboxymethyl)lysine levels in patients with type 2 diabetes: role of renal function. Am J Kidney Dis, 2001, 38, 785-91.
15. Uribarri J, Peppa M, Cai WJ, et al. Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients. J Am Soc Nephrol, 2003, 14, 728-31.
16. Wautier MP, Massin P, Guillausseau PJ, et al. N (carboxymethyl)lysine as a biomarker for microvascular complications in type 2 diabetic patients. Diabete Metab, 2003, 29, 44-52.
17. Turk Z, Ljubic S, Turk N, Benko B. Detection of autoantibodies against advanced glycation endproducts and AGE-immune complexes in serum of patients with diabetes mellitus. Clin Chim Acta, 2001, 303, 105-15.
18. Jeppsson JO, Jerntorp P, Sundkvist G, Englund H, Nylund V. Measurement of haemoglobin A1c by a new liquid-chromatographic assay: methodology, clinical utility, and relation to glucose tolerance evaluated. Clin Chem, 1986, 32, 1867-72.
19. Turk Z, Sesto M, Skodlar J, et al. Products of advanced glycation in patients with type 2 diabetes and vascular disease. Ann Clin Biochem, 2003, 40, 552-9.
20. Porterootin M, Pamplona R, Bellmunt MJ, Bergua M, Prat J. Glycemic control and in vivo non-oxidative Maillard reaction - urinary excretion of pyrraline in diabetes patients. Eur J Clin Invest, 1997, 27, 767-73.
21. Weiss MF, Rodby RA, Justice AC, Hricik DE. Free pentosidine and neopterin as markers of progression rate in diabetic nephropathy. Kidney Int, 1998, 54, 193-202.
22. Dolhoferbliesener R, Lechner B, Deppisch R, Ritz E, Gerbitz KD. Immunological determination of advanced glycosylation end-products in human blood and urine. Nephrol Dial Transplant, 1995, 10, 657-64.
23. Makita Z, Bucala R, Rayfield EJ, et al. Reactive glycosylation endproducts in diabetic uremia and treatment of renal failure. Lancet, 1994, 343, 1519-22.
24. Gugliucci A, Bendayan M. Renal fate of circulating advanced glycated end products (AGE): evidence for reabsorption and catabolism of AGE-peptides by renal proximal tubular cells. Diabetologia, 1996, 39, 149-60.
25. Forbes JM, Cooper ME, Oldfield MD, Thomas MC. Role of advanced glycation end products in diabetic nephropathy. Am J Kidney Dis, 2003, 41, S254-8.
26. Sakurai S, Yonekura H, Yamamoto Y, et al. The AGE-RAGE system and diabetic nephropathy. Am J Kidney Dis, 2003, 41, S259-63.
27. Tsilibary EC. Microvascular basement membranes in diabetes mellitus. J Pathol, 2003, 200, 537-46.